Consideration of cardiac function improvement effect of Omega-3 fatty acids(EPA +DHA)

Consideration of cardiac function improvement effect of Omega-3 fatty acids(EPA +DHA) - Consideration of cardiac function improvement effect of Omega-3 fatty acids(EPA +DHA)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017867

Enrollment

Registered

2015-07-01

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure patient with dyslipidemia

Interventions

Omega-3 fatty acid administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Chronic heart failure of LVEF >=40% of non-ischemic cardiomyopathy 2.EPA/AA ratio is less than 0.5 of dyslipidemia 3.Patient who is competent to understand the aim of this study and agree on it

Exclusion criteria

Exclusion criteria: 1. Patients who are bleeding 2. Past medical history of hypersensitivity 3. Judged as ineligible by physicians

Design outcomes

Primary

Measure	Time frame
LVEF, E/e', NTproBNP at 0, 6months after starting of treatment	—

Secondary

Measure	Time frame
TG,High sensitivity CRP, Quadrant blood fatty acid(EPA/AA)	—

Countries

Japan

Contacts

Public ContactKonomi Sakata

Kyorin University School of Medicine Department of Cardiology

sakata@ks.kyorin-u.ac.jp0422-47-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026